Veranex Launches MedTech’s First iCRO to Transform R&D Amid Tight Capital Climate
Veranex Launches Industry’s First Innovation CRO to Accelerate MedTech R&D in a Tight Capital Climate Veranex, a global leader in integrated product development and contract research services for medical technology,…
KalVista’s EKTERLY® (sebetralstat) Wins UK MHRA Nod as First Oral On-Demand HAE Treatment
KalVista Pharmaceuticals Secures UK MHRA Approval for EKTERLY® (sebetralstat), Paving the Way for First Oral On-Demand Treatment for Hereditary Angioedema in the Region KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage…
C2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers
C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative…
Enveric’s EB-003 Shows Promise in Preclinical PTSD Model
Enveric Biosciences’ Lead Candidate EB-003 Shows Promising Preclinical Efficacy in PTSD Model, Signaling a Potential Breakthrough in Neuroplasticity-Based Psychiatric Treatment Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company advancing a…
EyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades
EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered…
Vistagen Recognized for Exemplary Workplace Culture and Leadership in Mental Health
Vistagen Earns Dual Honors for Mental Health Advocacy and Exceptional Workplace Culture in 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company revolutionizing neuroscience with its novel nose-to-brain neurocircuitry platform,…
ZYUS Life Sciences Appoints CMO to Lead Phase 2 Cancer Pain Trial
ZYUS Life Sciences Appoints Dr. Julie Stakiw as Chief Medical Officer to Advance Phase 2 Oncology Pain Program and Strengthen Clinical Development Leadership In a pivotal step toward accelerating its…
JCR and Acumen Partner to Develop Alzheimer’s Therapy Using J-Brain Cargo®
JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical…
PCI Pharma Services Enters New Growth Phase with Strategic Investment
PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO)…
FDA Grants De Novo Nod to Reflow’s Spur Stent System
Reflow Medical Receives FDA De Novo Clearance for Spur Stent System, Marking a Breakthrough in Treatment of Below-the-Knee Peripheral Arterial Disease Reflow Medical, Inc., a pioneering company in the development…
CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines
CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully…
Samsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe
Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in…